摘要
Objective： The objective of this study is to evaluate the clinical efficacy of Xiaoyao Jieyu prescription （XJP） in the treatment of persistent postural-perceptual dizziness （PPPD）. Methods： A total of 33 PPPD patients were randomly divided into test group and control group. Two groups of patients were given psychological treatment. The test group was given XJP and the control group was given escitalopram. The course of treatment was 12 weeks. Before and after 4 weeks and 8 weeks and 12 weeks, the dizziness handicap inventory （DHI）, Hamilton anxiety scale （HAMA） and Hamilton Depression scale （HAMD） were used to evaluate the treatment effect. Results： The total scores of HAMA, HAMD, DHI and the respective factor scores of DHI significantly decreased in both groups after 4 weeks of treatment compared with those before the treatment （P 〈 0.01）. The DHI scores and the score of function, physiology at 8-week, 12-week, as well as the HAMA and HAMD scores at 4-week, 8-week, 12-week in the test group were significantly lower than those in the control group （P 〈 0.05）. The incidence of adverse reactions in the test group was significantly lower than the control group （P 〈 0.05）. Conclusion： XJP can improve the clinical symptoms of patients with PPPD. It can both improve the physical and functional symptoms of PPPD and reduce anxiety and depression. In the course of treatment, the adverse reaction of the prescription is less and mild. It has the advantages of high efficiency, safety, low price and easy access to materials.
目的：评价中药逍遥解郁方（XJP）治疗持续性姿势-知觉性头晕（PPPD）的临床疗效.方法：纳入33例确诊为PPPD的患者,随机分为试验组和对照组.两组患者均给以心理治疗.试验组给予口服逍遥解郁方,对照组给予口服艾司西酞普兰,疗程为12周.分别于治疗前及治疗4周、8周、12周末,采用眩晕残障程度评定量表（DHI）、汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表（HAMD）评估疗效.结果：两组患者在治疗4周后,HAMA、HAMD、DHI总评分及各因子评分即较治疗前显著降低（P〈0.01）;与对照组相比,试验组第8、12周的DHI总评分及功能、生理评分,第4、8、12周的HAMA、HAMD积分均明显低于同期对照组（P〈0.05）;不良反应发生率试验组明显低于对照组（P〈0.05）.结论：逍遥解郁方可全面改善PPPD患者的临床症状,降低PPPD患者的功能、生理症状积分,降低患者的焦虑、抑郁及头晕残障程度;在治疗过程中不良反应少而轻;具有高效、安全、价廉、易取材等优点.
